Building a Company the Unconventional Way
When Herriot Tabuteau launched Axsome Therapeutics in 2012, he deliberately broke from tradition. Rather than chase easy wins, he chose to focus on treatments for brain disorders, among the most difficult and unpredictable areas of drug development. He also decided to self-fund the company, drawing on his own background in medicine, decades of experience in biotech investing, and support from family and friends, rather than turning to venture capital.
“If you do things the same way as everybody else, you’re going to have the same outcomes as everybody else,” says Tabuteau, now 57.
From “Broom Closet” to Nasdaq Billionaire
Axsome began humbly in a small three-desk office in New York’s Rockefeller Center, jokingly nicknamed “the broom closet.” Today, the company is valued at $6.1 billion on the Nasdaq and has three drugs on the market with five more in development. Over the last year, Axsome generated $495 million in revenue, though it is still posting net losses as it scales.
Tabuteau’s personal 15% stake makes him a billionaire. If his projections hold, Axsome’s portfolio could eventually bring in $16.5 billion in annual sales, placing it among the world’s top 25 pharmaceutical firms.
A Haitian Childhood That Shaped Resilience
Born in Haiti, Tabuteau recalls a childhood marked by “physical, nutritional, emotional” neglect. At the age of nine, he moved to New York’s Upper East Side with his father and adoptive mother, where he grew up in the shadow of institutions such as Sloan Kettering and Rockefeller University. “I was just surrounded by science,” he reflects.
His academic path took him through Wesleyan University (molecular biology and biochemistry) and Yale School of Medicine, where he initially planned a career in neurosurgery. Disillusioned by the dissatisfaction of his physician mentors, however, he pivoted to finance, beginning at Goldman Sachs and later working at Bank of America Securities, S.A.C. Capital, and his own funds.
Wall Street Lessons Applied to Biotech
After two decades on Wall Street, Tabuteau had witnessed the successes and failures of countless biotech startups. He saw that most companies bet on a single drug, a strategy he thought too risky. Instead, he built Axsome with a portfolio approach and decided to run clinical trials in-house to cut costs and improve efficiency.
Although this drew skepticism, Phase III trials typically cost upwards of $50 million—Tabuteau’s team often managed them at 30% to 50% less. This allowed Axsome to sustain multiple trials even in its early, lean years.
Breakthrough with Auvelity
Axsome’s big turning point came in 2022 when the FDA approved Auvelity, a fast-acting antidepressant that can take effect in just one week compared to six to eight weeks for traditional treatments. Shares of Axsome surged 65% in a week, pushing its valuation to $3 billion.
Auvelity is on track to reach $500 million in sales this year, with analysts predicting it could become a blockbuster drug—potentially surpassing $1 billion annually. Legal protections now extend their exclusivity until at least 2038.
Strategic Acquisitions and Shrewd Deals
Tabuteau also used his finance expertise to expand Axsome’s pipeline. In 2022, the company acquired Sunosi, a treatment for excessive sleepiness, for $53 million. Within a year, Axsome sold the rights for Europe, the Middle East, and Africa for $66 million while retaining U.S. rights—quickly recouping its investment. Sunosi now generates more than $100 million annually.
The Next Frontier: Alzheimer’s Disease
Axsome’s next big test lies in securing FDA approval for a treatment targeting agitation in Alzheimer’s patients. Unlike antipsychotics, which carry dangerous risks including death, Axsome’s drug avoids those side effects. While Phase III results have been mixed, analysts expect demand for safer alternatives to drive approval.
If successful, the drug could generate $1.5 billion to $3 billion in annual sales, alongside Auvelity’s projected $1 billion to $3 billion, helping Axsome achieve its long-term revenue goals.
Small in Size, Big in Ambition
Despite its modest size, Axsome’s ambitions are vast. “We might be a small company in terms of size,” says Tabuteau, “but we’re not a small company in terms of fundamentals or in terms of ambition.”
With three drugs already on the market, five more in the pipeline, and a strategy rooted in both scientific rigor and financial discipline, Herriot Tabuteau’s journey from Haiti to Wall Street to biotech billionaire underscores the power of resilience, vision, and innovation.
Source: Adapted from Forbes, reporting by Jon D. Markman. This Haiti-born doctor Built A $6 Billion Business Developing Drugs For Depression And Alzheimer’s
